These are two different technologies, not two versions of the same idea. Fraxel is a non-ablative fractional laser: light, absorbed by water in the skin, delivered through an intact surface. Morpheus8 is radiofrequency microneedling: needles pushed into the skin, with electrical heating released from the needle tips.
Fraxel has cosmetic indications in its cleared text. Morpheus8 has none. Morpheus8's clearances read electrocoagulation and hemostasis (K192695, 2019) — surgical language for sealing tissue and stopping bleeding — and coagulation or contraction of soft tissue (K231790, 2023). Acne scars, wrinkles and laxity appear in neither. We were not able to confirm the exact wording of Fraxel's clearance, so its clearance number and indication list are not quoted here. Ask the clinic which Fraxel clearance and which wavelength they are treating you with, and for what.
That is a difference in what a regulator reviewed, not a measure of results. A 510(k) clearance means a device was judged substantially equivalent to an earlier one. It is not a finding that the treatment works, and off-label treatment with Morpheus8 is legal and completely routine.
The other big difference is where the depth comes from. With Fraxel, depth is a property of the wavelength: 1927 nm is absorbed very near the surface, 1550 nm reaches deeper. With Morpheus8, depth is a dial: the provider sets a needle length, from a fixed 0.5 mm resurfacing tip up to 7 mm on the larger tips.
Nothing enters the skin. The energy passes through the surface.
The operator manual states the pins are coated except for the distal 0.5 mm, so the heat is released in the dermis rather than at the entry point.
Because it targets a chromophore, the reaction depends partly on what is in the skin, including pigment.
Radiofrequency heating does not depend on skin colour, which is why this class is often described as colour-blind.
Ask the clinic which clearance and which wavelength apply to the treatment you are being offered, and what it names.
Above 62 mJ per pin, Morpheus8 is limited to skin types I to IV.
Acne scarring is the best-evidenced use of the RF microneedling class: a 2025 systematic review covered 16 studies and 481 patients, including six randomised trials.
Pigment change is the second most reported complication in FDA post-market data on RF microneedling: 41 of 224 reported events between 2013 and 2025.
This is the conventional clinical description of Fraxel recovery, not a figure from any FDA document or published study.
Skin barrier measurements peak on days one to three and return to baseline by day seven.
Ask what your main complaint is made of.
Almost no published study used Morpheus8. A PubMed search for the name returns 16 records and no randomised controlled trial. The research that supports RF microneedling was generated on other machines, mostly Lutronic, Jeisys, Pollogen and Lumenis devices. Readers searching for Morpheus8 are usually being shown other devices' results.
Six months is where that evidence stops. The longest properly measured follow-up in the literature is six months after the final treatment. Clinic claims of one to three years have no published source.
One risk deserves naming, because the marketing does not. Fat loss is the third most reported complication in FDA post-market data on RF microneedling, 26 of 224 reported events. There is no published incidence rate, no case series describing it, and no established treatment. Pulling the other way, a 2024 study that measured the fat layer under the chin by ultrasound after microneedling radiofrequency found no significant change; its title says "without lipolysis." Both facts are true, and the difference is likely depth and energy.
If you get cold sores, tell your provider at booking. Either treatment can reactivate the virus, and antiviral medication is started in advance rather than after a blister appears. For laser resurfacing this is well documented; for RF microneedling there is no published data, and the precaution is carried over.
Also mention a pacemaker or implantable defibrillator, or metal implants near the treatment area, before a radiofrequency treatment. That is a labelled contraindication for RF devices and a question for your cardiology team.